Melinta Therapeutics Stock Price, News & Analysis (NASDAQ:MLNT)

$15.60 0.80 (5.41 %)
(As of 12/14/2017 01:45 PM ET)
Previous Close$14.80
Today's Range$14.80 - $15.85
52-Week Range$10.25 - $37.00
Volume215,900 shs
Average Volume224,999 shs
Market Capitalization$162.53 million
P/E RatioN/A
Dividend YieldN/A

About Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics logoMelinta Therapeutics, Inc., formerly Cempra, Inc., is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP). Solithromycin has therapeutic potential and activity to target pathogenic bacteria. It has completed two pivotal Phase III trials for solithromycin to treat CABP, as of December 31, 2016. Its Fusidic acid is an antibiotic and the Company is exploring its use for the long-term oral treatment for refractory bone and joint infections (BJI), including prosthetic joint infections, which are caused by staphylococci, including S. aureus, methicillin-resistant S. aureus and other gram-positive bacteria.

Receive MLNT News and Ratings via Email

Sign-up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs


Debt-to-Equity Ratio0.03%
Current Ratio11.49%
Quick Ratio11.49%


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$18.02 million
Price / Sales9.09
Cash FlowN/A
Price / CashN/A
Book Value$17.50 per share
Price / Book0.89


Trailing EPS($7.34)
Net Income$-117,960,000.00
Net Margins-500.05%
Return on Equity-45.72%
Return on Assets-35.83%


Outstanding Shares10,500,000

Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions

What is Melinta Therapeutics' stock symbol?

Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."

How were Melinta Therapeutics' earnings last quarter?

Melinta Therapeutics, Inc. (NASDAQ:MLNT) released its quarterly earnings data on Thursday, October, 27th. The biotechnology company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.64) by $0.02. The biotechnology company had revenue of $4 million for the quarter, compared to analysts' expectations of $3.90 million. Melinta Therapeutics had a negative return on equity of 45.72% and a negative net margin of 500.05%. The firm's quarterly revenue was up 60.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.63) earnings per share. View Melinta Therapeutics' Earnings History.

Where is Melinta Therapeutics' stock going? Where will Melinta Therapeutics' stock price be in 2017?

13 analysts have issued twelve-month price objectives for Melinta Therapeutics' shares. Their forecasts range from $2.00 to $28.00. On average, they anticipate Melinta Therapeutics' stock price to reach $6.46 in the next twelve months. View Analyst Ratings for Melinta Therapeutics.

What are Wall Street analysts saying about Melinta Therapeutics stock?

Here are some recent quotes from research analysts about Melinta Therapeutics stock:

  • 1. According to Zacks Investment Research, "Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina. " (11/16/2017)
  • 2. Robert W. Baird analysts commented, "Cempra announced this morning that the MAA filed in Europe has been withdrawn. We believe it is likely due to the same safety concerns brought up by the FDA. At this point, the path forward for solithromycin appears to us to be a dead end and any additional expenditures will only diminish the company's otherwise attractive cash position. We reiterate our Underperform rating." (3/28/2017)
  • 3. Stifel Nicolaus analysts commented, "Incremental solithromycin updates provided on management's 4Q16 earnings announcement/call now meaningfully increase the likelihood this asset ' in its current formulation ' is unlikely to represent a source of any future value. In addition to FDA seemingly reiterating its stance on wanting 9,000 patients of additional CABP data to assuage hepatotoxicity concerns, EMA is now requesting additional data and management's commentary would suggest any regulatory path forward here is likely to prove challenging. Solithromycin also failed to achieve non-inferiority within the primary cohort of the P3 SOLITAIRE-U trial (gonorrhea), the NASH study has been suspended, and the COPD study has been closed. We've removed all solithromycin-related value (ex-Japan) from our model and believe any viable commercialization argument for Taksta is likely to hinge on YE17 P2 prosthetic joint infection data. Target decreased to $4 (previously $8)." (3/1/2017)

Who are some of Melinta Therapeutics' key competitors?

Who are Melinta Therapeutics' key executives?

Melinta Therapeutics' management team includes the folowing people:

  • Kevin T. Ferro, Chairman of the Board (Age 45)
  • Daniel M. Wechsler, President, Chief Executive Officer, Director (Age 46)
  • Paul Estrem, Chief Financial Officer
  • John D. Bluth, Executive Vice President - Investor Relations and Corporate Communications (Age 44)
  • Lyn Baranowski, Senior Vice President - Corporate Development and Strategy
  • Peter DiRoma, Senior Vice President - Regulatory Affairs and Quality Assurance
  • Erin M. Duffy Ph.D., Chief Scientific Officer (Age 45)
  • Suzie Paulson, Vice President of Human Resources
  • Kevin Conway, Vice President - Program Management and Technical Operations
  • Sue Cammarata M.D., Chief Medical Officer

How do I buy Melinta Therapeutics stock?

Shares of Melinta Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Melinta Therapeutics' stock price today?

One share of Melinta Therapeutics stock can currently be purchased for approximately $15.60.

How big of a company is Melinta Therapeutics?

Melinta Therapeutics has a market capitalization of $162.53 million and generates $18.02 million in revenue each year. The biotechnology company earns $-117,960,000.00 in net income (profit) each year or ($7.34) on an earnings per share basis. Melinta Therapeutics employs 45 workers across the globe.

How can I contact Melinta Therapeutics?

Melinta Therapeutics' mailing address is 300 George St Ste 301, NEW HAVEN, CT 06511-6663, United States. The biotechnology company can be reached via phone at +1-312-7670291 or via email at [email protected]

MarketBeat Community Rating for Melinta Therapeutics (MLNT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  349 (Vote Outperform)
Underperform Votes:  230 (Vote Underperform)
Total Votes:  579
MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Melinta Therapeutics (NASDAQ:MLNT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score:
Ratings Breakdown: 1 Sell Rating(s)
11 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
11 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
12 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
11 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.12$12.12$13.11$13.01
Price Target Upside: 23.06% downside426.86% upside316.19% upside242.37% upside

Melinta Therapeutics (NASDAQ:MLNT) Consensus Price Target History

Price Target History for Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics (NASDAQ:MLNT) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/30/2017GabelliUpgradeSell -> HoldHighView Rating Details
11/30/2017Ladenburg Thalmann Financial ServicesUpgradeNeutral -> BuyHighView Rating Details
11/1/2017Robert W. BairdUpgradeUnderperform -> Neutral$2.00N/AView Rating Details
10/26/2017Jefferies GroupReiterated RatingHold -> NeutralN/AView Rating Details
8/10/2017Roth CapitalDowngradeBuy -> Neutral$8.00 -> $4.00HighView Rating Details
8/10/2017Stifel NicolausReiterated RatingHold$4.00HighView Rating Details
1/12/2017J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
1/2/2017CowenReiterated RatingHoldN/AView Rating Details
1/2/2017Cantor FitzgeraldSet Price TargetBuy$28.00N/AView Rating Details
12/30/2016Needham & Company LLCReiterated RatingHoldN/AView Rating Details
12/30/2016Morgan StanleyUpgradeUnderweight -> Equal Weight$5.00 -> $5.00N/AView Rating Details
12/29/2016WBB SecuritiesDowngradeBuy -> Hold$40.00 -> $4.00N/AView Rating Details
12/29/2016S&P Equity ResearchBoost Price Target$2.65 -> $3.15N/AView Rating Details
12/20/2016SunTrust BanksDowngradeBuy -> Sell$18.00 -> $5.00N/AView Rating Details
11/8/2016Royal Bank of CanadaReiterated RatingBuy$27.50N/AView Rating Details
11/2/2016Raymond James FinancialReiterated RatingOutperform -> Market PerformN/AView Rating Details
5/10/2016Janney Montgomery ScottReiterated RatingHoldN/AView Rating Details
5/2/2016Leerink SwannReiterated RatingHoldN/AView Rating Details
(Data available from 12/14/2015 forward)


Melinta Therapeutics (NASDAQ:MLNT) Earnings History and Estimates Chart

Earnings by Quarter for Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics (NASDAQ MLNT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.32)($0.23)$3.58 million$0.86 millionViewListenView Earnings Details
4/28/2017Q1 2017($0.53)($0.37)$3.55 million$4.87 millionViewN/AView Earnings Details
2/28/2017Q4 2016($0.57)($0.60)$4.19 million$7.95 millionViewListenView Earnings Details
10/27/2016Q3($0.64)($0.62)$3.90 million$4.00 millionViewListenView Earnings Details
8/1/2016Q2($0.67)($0.51)$3.89 million$3.42 millionViewN/AView Earnings Details
5/1/2016Q1($0.63)($0.61)$3.94 million$2.70 millionViewN/AView Earnings Details
2/24/2016Q4($0.59)($0.48)$3.89 million$5.79 millionViewListenView Earnings Details
10/22/2015Q315($0.52)($0.63)$4.70 million$2.50 millionViewListenView Earnings Details
7/29/2015Q2($0.41)($0.57)$4.60 million$5.05 millionViewListenView Earnings Details
4/30/2015Q1($0.43)($0.41)$2.90 million$13.96 millionViewListenView Earnings Details
2/25/2015Q414($0.46)($0.46)$3.50 million$2.47 millionViewListenView Earnings Details
10/29/2014Q314($0.59)($0.34)$1.59 million$7.77 millionViewN/AView Earnings Details
7/29/2014Q214($0.56)($0.49)$2.56 million$1.90 millionViewN/AView Earnings Details
4/29/2014Q114($0.48)($0.51)$2.10 million$3.10 millionViewN/AView Earnings Details
2/27/2014Q413($0.42)($0.51)$1.25 million$2.07 millionViewN/AView Earnings Details
10/29/2013Q313($0.29)($0.41)$0.46 million$1.20 millionViewN/AView Earnings Details
7/30/2013Q3 2013($0.42)($0.16)$5.13 million$4.60 millionViewN/AView Earnings Details
11/8/2012Q312($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Melinta Therapeutics (NASDAQ:MLNT) Earnings Estimates

Current Year EPS Consensus Estimate: $-4.97 EPS
Next Year EPS Consensus Estimate: $-5.15 EPS


Dividend History for Melinta Therapeutics (NASDAQ:MLNT)

No dividend announcements for this company have been tracked by

Insider Trades

Melinta Therapeutics (NASDAQ MLNT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 17.80%
Insider Trades by Quarter for Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics (NASDAQ MLNT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/8/2017Dov A Md GoldsteinDirectorSell150,000$3.55$532,500.00View SEC Filing  
1/13/2017Dov A Md GoldsteinDirectorSell105,460$3.40$358,564.00View SEC Filing  
1/6/2017Dov A Md GoldsteinDirectorSell937,600$3.41$3,197,216.00View SEC Filing  
1/3/2017David N GillDirectorBuy5,000$2.94$14,700.00View SEC Filing  
3/1/2016David MooreInsiderBuy500$16.18$8,090.00View SEC Filing  
1/4/2016Dov A. Md GoldsteinDirectorSell842$30.06$25,310.52View SEC Filing  
12/15/2015David W. OldachinsiderSell10,000$30.27$302,700.00View SEC Filing  
11/9/2015David W. OldachinsiderSell12,200$28.78$351,116.00View SEC Filing  
10/26/2015Garheng KongDirectorBuy2,830$17.43$49,326.90View SEC Filing  
6/22/2015Dov A Md GoldsteinDirectorSell50,000$35.74$1,787,000.00View SEC Filing  
5/23/2014John JohnsonDirectorBuy10,000$9.10$91,000.00View SEC Filing  
6/19/2013P Sherrill NeffDirectorBuy265,000$7.00$1,855,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Melinta Therapeutics (NASDAQ MLNT) News Headlines

 Brokerages Expect Cempra, Inc. (MLNT) Will Post Quarterly Sales of $2.48 Million Brokerages Expect Cempra, Inc. (MLNT) Will Post Quarterly Sales of $2.48 Million - December 6 at 5:54 AM
ETFs with exposure to Melinta Therapeutics, Inc. : December 5, 2017ETFs with exposure to Melinta Therapeutics, Inc. : December 5, 2017 - December 5 at 6:16 PM
Zacks: Brokerages Anticipate Cempra, Inc. (MLNT) to Announce -$0.74 Earnings Per ShareZacks: Brokerages Anticipate Cempra, Inc. (MLNT) to Announce -$0.74 Earnings Per Share - December 4 at 1:26 PM
Gabelli Weighs in on Cempra, Inc.s FY2017 Earnings (MLNT)Gabelli Weighs in on Cempra, Inc.'s FY2017 Earnings (MLNT) - December 4 at 1:52 AM
Cempra (MLNT) Cut to Strong Sell at ValuEngineCempra (MLNT) Cut to Strong Sell at ValuEngine - December 3 at 7:30 AM
Cempra (MLNT) Stock Rating Upgraded by GabelliCempra (MLNT) Stock Rating Upgraded by Gabelli - November 30 at 11:22 AM
Cempra (MLNT) Lifted to "Buy" at Ladenburg Thalmann Financial ServicesCempra (MLNT) Lifted to "Buy" at Ladenburg Thalmann Financial Services - November 30 at 7:34 AM
Cempra, Inc. (MLNT) Given Average Rating of "Hold" by AnalystsCempra, Inc. (MLNT) Given Average Rating of "Hold" by Analysts - November 30 at 4:08 AM
Melinta Therapeutics, Inc. – Value Analysis (NASDAQ:MLNT) : November 28, 2017Melinta Therapeutics, Inc. – Value Analysis (NASDAQ:MLNT) : November 28, 2017 - November 28 at 6:20 PM
Melinta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MLNT-US : November 27, 2017Melinta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MLNT-US : November 27, 2017 - November 27 at 4:55 PM
Why Earnings Season Could Be Great for Cempra (MLNT) - NasdaqWhy Earnings Season Could Be Great for Cempra (MLNT) - Nasdaq - November 23 at 6:31 AM
Cempra, Inc. (MLNT) Stock Rating Upgraded by Zacks Investment ResearchCempra, Inc. (MLNT) Stock Rating Upgraded by Zacks Investment Research - November 18 at 10:52 PM
 Analysts Anticipate Cempra, Inc. (MLNT) Will Announce Quarterly Sales of $2.48 Million Analysts Anticipate Cempra, Inc. (MLNT) Will Announce Quarterly Sales of $2.48 Million - November 18 at 11:58 AM
 Brokerages Anticipate Cempra, Inc. (MLNT) Will Announce Earnings of -$0.82 Per Share Brokerages Anticipate Cempra, Inc. (MLNT) Will Announce Earnings of -$0.82 Per Share - November 16 at 3:10 AM
Melinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of AcneMelinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of Acne - November 13 at 5:59 PM
Head-To-Head Comparison: Cempra (MLNT) and Its PeersHead-To-Head Comparison: Cempra (MLNT) and Its Peers - November 9 at 5:30 PM
<html id= (MLNT) versus Its Competitors Head-To-Head Comparison - November 9 at 1:12 AM
<html id= (MLNT) Rating Increased to Hold at ValuEngine - November 8 at 5:45 PM

SEC Filings

Melinta Therapeutics (NASDAQ:MLNT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Melinta Therapeutics (NASDAQ:MLNT) Income Statement, Balance Sheet and Cash Flow Statement


Melinta Therapeutics (NASDAQ MLNT) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.